Abstract

ApoA-II is the second most abundant protein on HDL making up ∼20% of the total protein but its functions have still only been partially characterized. Recent methodological improvements have allowed for the recombinant expression and characterization of human apoA-II which shares only 55% sequence homology with murine apoA-II. Here we describe the purification of the two most common polymorphic variants of apoA-II found in inbred mouse strains, differing at 3 amino acid sites. C57BL/6 mice having variant apoA-IIa have lower plasma HDL levels than FVB/N mice that have variant apoA-IIb. Characterization of the helical structure of these two variants reveals a more alpha-helical structure for the FVB/N apoA-II. These changes do not alter the lipid or HDL binding of the two apoA-II variants, but significantly increase the ability of the FVB/N variant to promote both ABCA1 and ABCG1 mediated cellular cholesterol efflux. These differences may be differentially altering plasma HDL apoA-II levels. In vivo, neither C57 nor FVB apoA-II protein levels are affected by the absence of apoE, while an apoE/apoA-I double deficiency results in a 50% decrease of plasma FVB apoA-II but results in undetectable levels of C57 apoA-II in the plasma. FVB apoA-II is able to form an HDL particle in the absence of apoE or apoA-I.

Highlights

  • Cardiovascular disease including atherosclerosis continues to be a leading cause of morbidity and mortality

  • Using a protocol modified from Smith and colleagues we were able to purify more than 2 mg mouse apoA-II recombinant protein per liter of starting culture (Figure 1) [21]

  • Our results demonstrate the lack of apoE, apoA-I, or both proteins has no effect on Apoa2 liver expression in either strain, nor was there a significant difference between the strains

Read more

Summary

Introduction

Cardiovascular disease including atherosclerosis continues to be a leading cause of morbidity and mortality. In humans there are conflicting results, with some studies showing an inverse correlation between plasma apoA-II levels and coronary atherosclerosis and future disease risk [8,9]. Human apoA-II deficiency does not impart increased risk of atherosclerotic disease [10]. ApoA-II overexpression increases aortic lesion size despite increased plasma HDL levels, while knocking out apoA-II increases the atherogenic properties of murine HDL [11,12]. Several mouse apoA-II sequence variants have been identified with apoA-IIa and apoA-IIb being among the most common of the variants, differing at 3 amino acid sites in the mature apoprotein (D20E, M26V, A28V, respectively) [14]. Among inbred mouse strains the C57BL/6 (C57), possessing the apoA-IIa variant, is highly athero-susceptible while the FVB/N (FVB) expressing the apoA-IIb is athero-resistant [15,16]. The FVB strain has double the plasma apoA-II concentration of the

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.